Mary Devlin Capizzi

Phone: (202) 230-5101 (202) 230-5101
Fax: (202) 842-8465


Mary Devlin Capizzi counsels individual corporations and consortia clients (comprised of industry, government and academia representatives) on a range of compliance matters involving regulatory, legislative, scientific and policy issues. She represents clients in the pharmaceutical, biotechnology, medical device, health, nutrition, chemical and technology sectors. Mary has represented clients before the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Health Canada, the Medicines and Healthcare Products Regulatory Agency (MHRA), the U.S., Japanese and European Pharmacopoeias (USP, JP and EP), the International Organization for Standardization (ISO) and other regulatory, governmental and scientific agencies in the United States and other world regions. A number of the industry consortia she serves are focused on joint technology development and data sharing initiatives.

Mary currently serves as a managing partner of the firm and is a member of the Women's Leadership Committee and the Government and Regulatory Affairs Group. She recently completed a three-year term as the Executive Partner responsible for the firm’s regulatory practices and marketing and business development functions. Formerly she served as the first chair of the firm’s Professional Development Committee.

Prior to joining the firm, Mary served on the New York City-based legal team that represented the Bank Advisory Committees for Brazil and Mexico in connection with the restructuring of their sovereign external debt. She is a fluent Spanish speaker and completed foreign study programs at La Universidad de San Luis in Madrid, Spain; Universidad Internacional, Center for Bilingual Multicultural Studies in Cuernavaca, Mexico; Universitá di Dallas in Rome, Italy; and L’Ecole des Cadres in Paris, France.


Mary enjoys facilitating complex industry-wide initiatives. She has almost twenty years of experience in the formation and management of focused industry consortia. She has served as legal counsel and secretariat for a range of consortia and coalitions and plays a leading role in facilitating consensus-building processes and assisting groups in efficiently devising and executing initiatives. She has represented clients before the U.S. Food and Drug Administration (FDA), Federal Trade Commission (FTC), U.S., Japanese and European Pharmacopoeias (USP, JP and EP), Health Canada, European Medicines Agency (EMA), The UK’s Medicines and Healthcare products Regulatory Agency (MHRA), International Conference on Harmonisation (ICH) and International Organization for Standardization (ISO).

  • Mary worked with industry leaders to establish the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS), an association of research-based pharmaceutical companies that seeks to advance the science of orally-inhaled and nasal drug products by collecting and analyzing data and conducting joint research and development projects. She serves as legal counsel to IPAC-RS and in that role helps identify the consortium’s priorities and implement its strategic plan. She oversees the planning for interactions with health regulatory agencies in the US and globally and plays a key role in drafting comment letters on guidance documents and proposed rules that impact orally-inhaled and nasal drug products.
  • Mary worked with industry leaders to establish both the International Pharmaceutical Privacy Consortium (IPPC) and Medical Device Privacy Consortium (MDPC). She serves as legal counsel to these two groups. In that role she has helped in the creation and implementation of strategic plans, preparation of industry comments on legislative and regulatory proposals and development and promotion of positions.
  • Mary worked with industry leaders to establish Rx-360, an international pharmaceutical supply chain consortium that serves to protect patient safety by sharing information and developing processes to enhance the integrity of the healthcare supply chain and the quality of materials within the supply chain. She guided Rx-360 from a newly formed consortium in 2009 until it was launched into a free-standing trade association with a full-time support staff in 2016.
  • Mary has extensive experience counseling global companies on data privacy and security issues, including the development of privacy policies and procedures, undertaking gap assessments to compare practices to legal requirements and best practices, and assisting in the development of data protection programs.
  • Mary consults with individual clients on clinical research and contracting matters, manufacturing, and commercial operations, scientific, legal, regulatory and policy issues relating to product development, quality control and assurance, and supply chain security.


Bar Admissions

  • District of Columbia
  • New York


  • Emory University, J.D., 1994
  • University of Dallas, Graduate School of Management, M.B.A., 1989
  • University of Dallas, B.A., 1988


  • Drug Information Association
  • Food Drug and Law Institute
  • John Carroll Society
  • BNA, Pharmaceutical Law & Industry Report, Advisory Board
  • Regulatory Affairs Professional Society
  • Legal Counsel for the Elderly, Volunteer Attorney
  • Legal Clinic for the Homeless, Hispanic Project, Volunteer Attorney